Tests saroglitazar in adults with liver scarring from cholestatic liver disease
Tests how the body handles saroglitazar in people with moderate liver impairment from cirrhosis.
Key facts
- Who runs it
- Zydus Therapeutics Inc.
- Where
- Indianapolis, United StatesSee the site
- Trial code
- Registry title
- Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 6 people, planned
- Started
- 5 Aug 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Treatments tested
- Saroglitazar Magnesium 1 mg
- Record updated
- 14 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cirrhosis (scarred liver) caused by cholestatic liver disease and moderately reduced liver function. It studies how the body handles saroglitazar magnesium 1 mg given on alternate days.
- Age
- 18 to 80 years
- Sex
- Men and women
- Disease stage
- Cirrhosis due to cholestatic liver disease with moderate hepatic impairment, Child-Pugh Turcotte score 7 to 9
- Earlier treatment
- Must not have received another investigational drug within 30 days or 5 half-lives (whichever is longer) before saroglitazar. Must not have received blood products within 1 month of check-in.
- Biomarker or test result
- Alkaline phosphatase above the upper limit of normal; alanine aminotransferase/aspartate aminotransferase no more than 10 times the upper limit of normal; other blood values within set limits (neutrophils, platelets, hemoglobin, α-fetoprotein); body mass index 18.0 to 48.0 kg/m2
Main reasons for not taking part
- Other causes of liver disease, such as fatty liver disease, autoimmune hepatitis or hepatitis B or C
- HIV type 1 antibody positive
- Pregnant or breastfeeding
- Estimated glomerular filtration rate below 45 mL/min/1.73 m2
- Cancer in the last 3 years (some skin and in situ cancers excepted)
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Male and/or female aged 18 to 80 years (both inclusive) at the time of signing the ICF
- Body mass index within the range 18.0 to 48.0 kg/m2 (inclusive) at screening
- Ability to swallow and retain oral medication
- Subjects having documented history of hepatic impairment with cirrhosis due to cholestatic liver disease having Child-Pugh Turcotte score 7 to 9. If the hepatic impairment classification for the subject is not the same at screening and Day -1, enrolment of the subject into a hepatic category group will be at the discretion of the investigator
- Laboratory test values must be clinically acceptable to the investigator and meet all the following parameters at screening:; Alkaline Phosphatase > upper limit of normal Alanine aminotransferase/Aspartate aminotransferase value ≤ 10 × upper limit of normal Absolute neutrophil count ≥ 750/mm3 Platelets ≥ 25,000/mm3 Hemoglobin ≥ 8 g/dL α-fetoprotein <50 ng/mL or 50-80 ng/mL with negative imaging study (Ultrasound [US], computed tomography scan [CT], Magnetic Resonance Imaging [MRI]). Imaging study that excluded presence of liver cancer (US in the preceding 6 months and CT or MRI in the preceding 1 year)
- Must provide written informed consent and agree to comply with the trial protocol
Who cannot take part
- Any major surgery within 3 months of screening
- Human immunodeficiency virus type 1 antibody positive at screening
- Any significant or unstable medical condition or other instability that would prevent the subject from participating in the study as determined by the investigator
- History of malignancy of any type in the last 3 years of screening, with the exception of the following: in situ cervical or breast cancer or surgically excised non-melanoma skin cancers (i.e., basal cell or squamous cell carcinoma)
- History of stomach or intestinal surgery or resection within 6 months of screening that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed)
- The history of any significant drug allergy (such as anaphylaxis) deemed clinically relevant by the investigator
- Active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment or symptoms of active infectious disease within 2 weeks of screening
- Other known causes of liver disease, such as non-alcoholic steatohepatitis , alcoholic steatohepatitis, autoimmune hepatitis, or acute or chronic viral hepatitis (including Hepatitis B and C) as determined by the investigator and subject's medical records
- Subjects who have had a change in hepatic disease status within 30 days of screening, as documented by the subject's medical history and deemed clinically significant by the investigator
- Subjects having - History of gastrointestinal bleeding within 1 month of screening. Current functioning organ transplant. Evidence of severe ascites requiring frequent paracentesis in the opinion of the investigator
- Receiving or has received any investigational drug within 30 days or 5 half-lives (whichever is longer), before receiving Saroglitazar Magnesium
- Donation of blood or blood products within 3 months of screening
- Estimated glomerular filtration rate (<45 mL/min/1.73 m2 by CKD-EPI 2021 formula at screening
- Any individual with poor peripheral venous access
- Receipt of blood products within 1 month of check in
- Pregnancy-related exclusions, including:; Pregnant/lactating female (including positive pregnancy test at screening) Pregnancy should be avoided by male and female subjects either by true abstinence or the use of an acceptable effective contraceptive measures for the duration of the study and for at least 1 month after the end of the study treatment
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- Indianapolis, IndianaHospital not named in the registryContact: Mandy CruzTaking people
About the trial
What the trial wants to find out
Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease
The group in the trial
- Saroglitazar Magnesium 1 mgTreatment being tested
Saroglitazar Magnesium 1 mg tablet orally administered on alternate days in the morning before breakfast without food, for the duration of treatment (29 days)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, Open-label, Single Arm Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Saroglitazar Magnesium Dosed on Alternate Days in Subjects Having Moderate Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
- Plain-language title
- Tests saroglitazar in adults with liver scarring from cholestatic liver diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06825559, who can take part
- Record updated
- 14 September 2026